2009 was a solid year for sanofi-aventis
2010? Not so solid. Colon cancer drug Eloxatin now has generic competition from Teva Pharmaceuticals
EPS on an adjusted basis are expected to come in 2% to 5% higher. But -- and this is a big but -- that assumes no generic competition for Lovenox.
Now I realize it's difficult for Sanofi to determine if or when the FDA will approve the generic versions -- it's a complicated drug and the agency has been working on applications filed by generic-drug makers including Teva and Momenta Pharmaceuticals
Unlike Bristol-Myers and Eli Lilly
This year however, I think it's clear that the patent cliff has the upper hand.
Let us know what you think in Motley Fool CAPS. Make an out- or underperform call on these companies; post a pitch about whether you think Sanofi is a good long-term play. It's free. It's fun. And, it's Foolish.